INPULSIS-ON shows ofev slows progression of IPF

New study results provide evidence that Ofev ® (nintedanib) slows progression of IPF beyond four years with consistent safetyINPULSIS ®-ON study indicates safety and efficacy of Ofev®(nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1Results from INPULSIS ®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet Respiratory Medicine1 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news